As part of the VE-BASKET multi-cohort study for non-melanoma cancers (15), BRAF inhibition with Vemurafenib led to an objective response rate (ORR) of 25% in a cohort of 24 adult patients with relapsed/progressive BRAFV600E mutant gliomas. Here, BRAF is linked to cancer.